Gene Expression and Protein Abundance of Hepatic Drug Metabolizing Enzymes in Liver Pathology
Hepatic drug metabolizing enzymes (DMEs) markedly affect drug pharmacokinetics. Because liver diseases may alter enzymatic function and in turn drug handling and clinical efficacy, we investigated DMEs expression in dependence on liver pathology and liver failure state. In 5 liver pathologies (hepat...
Main Authors: | Marek Drozdzik, Joanna Lapczuk-Romanska, Christoph Wenzel, Sylwia Szelag-Pieniek, Mariola Post, Łukasz Skalski, Mateusz Kurzawski, Stefan Oswald |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/9/1334 |
Similar Items
-
Monocarboxylate Transporter 1 (MCT1) in Liver Pathology
by: Marek Droździk, et al.
Published: (2020-02-01) -
Identifying Differentially Expressed MicroRNAs, Target Genes, and Key Pathways Deregulated in Patients with Liver Diseases
by: Maryam Gholizadeh, et al.
Published: (2020-10-01) -
Membrane Carriers and Transporters in Kidney Physiology and Disease
by: Marek Drozdzik, et al.
Published: (2021-04-01) -
Extrahepatic Drug Transporters in Liver Failure: Focus on Kidney and Gastrointestinal Tract
by: Marek Droździk, et al.
Published: (2020-08-01) -
Impact of kidney dysfunction on hepatic and intestinal drug transporters
by: Marek Droździk, et al.
Published: (2021-11-01)